LY 03017
Alternative Names: LPM-526000133; LPM526000133 Fumarate; LY-03017Latest Information Update: 24 May 2024
At a glance
- Originator Luye Pharma Group
- Class Antipsychotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Schizophrenia
Most Recent Events
- 03 May 2024 Preclinical trials in Schizophrenia in China (PO), before May 2024
- 03 May 2024 Luye Pharma Group plans a phase I trial for Schizophrenia (In volunteers) in China (PO), in May 2024 (NCT06388551)